Generic Drug News and Research

RSS

Generic Drugs are official nonbrand names by which medicines are known. Generic names usually refer to the chemical name of the drug.

HCCI's report shows facility prices outpaced general inflation for the privately insured under 65

Rising prices for care were the chief driver of health care costs for privately insured Americans in 2010, according to the first report from the newly formed Health Care Cost Institute.

21 May 2012

Teva first quarter net revenues increase 25% to $5.1 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended March 31, 2012.

9 May 2012

PharMerica first quarter net income increases to $5.6 million

PharMerica Corporation, a national provider of institutional pharmacy and hospital pharmacy management services, today reported its financial results for the first quarter of 2012.

3 May 2012

Teva, Mylan settle patent infringement litigation for Nuvigil

Teva Pharmaceutical Industries Ltd., one of the world's largest producers of pharmaceuticals, announces that it has settled patent infringement litigation regarding U.S. Patent Number 7,132,570 (the "'570 patent") with respect to Mylan Inc.'s ANDA for Teva's wakefulness product NUVIGIL (armodafinil) tablets.

30 Apr 2012

Leahy introduces generic drug label legislation

The measure, which was introduced in the Senate and has a House companion, would permit generic drug companies to update safety information about the drugs they manufacture, enabling patients to sue the companies for failing to issue warnings about risks. It aims to address a gap in the law that allows people to sue brand-name drug makers for insufficient warnings, but not generics manufacturers.

20 Apr 2012

First Edition: April 18, 2012

Today's health policy headlines include reports about how a one-year experiment on Medicare competitive bidding showed positive results in terms of saving money as well as reducing waste and fraud.

19 Apr 2012

Supreme Court rules generic drug makers can challenge branded drug companies' wording in patent applications

The U.S. Supreme Court handed a victory to generic-drug companies Tuesday, ruling they can file certain legal counterclaims against brand-drug companies in an effort to get their cheaper copycat medicines on the market. The court, in an opinion written by Justice Elena Kagan, ruled unanimously that generic-drug makers should be allowed to challenge the way brand-name manufacturers describe their patents to the Food and Drug Administration.

19 Apr 2012

First Edition: April 18, 2012

Today's headlines include reports about the latest Capitol Hill developments related to the budget.

18 Apr 2012

Synthon receives tentative approval for tadalafil tablets

Synthon has announced that its subsidiary Synthon Pharmaceuticals, Inc. has received tentative approval from the U.S. Food and Drug Administration (FDA) for its abbreviated new drug application for tadalafil tablets, 20 mg on April 13, 2012. Synthon's product is a generic and bioequivalent version of Eli Lilly & Co and United Therapeutics’ Adcirca® tablets, which are indicated for the treatment of pulmonary arterial hypertension to improve exercise ability.

16 Apr 2012

Teva's ANDA for Provigil entitled to 180-day exclusivity

Teva Pharmaceutical Industries Ltd. announces that the FDA has decided that its wholly owned subsidiary, Teva Pharmaceuticals USA, is sole first-to-file for both Orange Book patents listed for Provigil (modafinil) and therefore Teva's ANDA alone is entitled to 180-day exclusivity.

6 Apr 2012

Teva reports successful outcome of three debut financings

Teva Pharmaceutical Industries Limited announced today that it successfully priced its debut EUR 1 billion and CHF 450 million debt offerings, and that it entered into a JPY 100 billion senior unsecured fixed-rate syndicated term loan facility.

2 Apr 2012

Teva launches generic Avalide and Avapro Tablets

Teva Pharmaceutical Industries Ltd. announced today that it has commenced commercial launch of both Irbesartan and Irbesartan-Hydrochlorothiazide Tablets, the Company's generic versions of Sanofi Aventis' high blood pressure treatments, Avapro and Avalide Tablets.

2 Apr 2012

Teva introduces generic Provigil

Teva Pharmaceutical Industries Ltd. announces the launch of the authorized generic of Provigil (modafinil).

31 Mar 2012

Consumer should be centre of care when offering alternative medicine brands

NPS is reminding pharmacists to place patient care first and avoid multiple switching of medicine brands for patients who may be at higher risk of confusion from switching, as price disclosure arrangements come into effect this weekend.

29 Mar 2012

Morning after pills difficult for teenagers to procure

Quite a few U.S. pharmacies may give teen girls incorrect information over the phone about whether they can get the morning-after pill. The pill is a form of emergency contraception taken within 72 hours after unprotected sex to prevent pregnancy without a prescription, a new study suggests.

27 Mar 2012

Teva, IVAX receive FDA approval for generic Lexapro to treat depression and GAD

The U.S. Food and Drug Administration today approved the first generic Lexapro (escitalopram tablets) to treat both depression and generalized anxiety disorder in adults.

27 Mar 2012

Health solutions developed in lower-income countries will help bring end to aid

"It is not just quantity of aid that counts nowadays, but the quality and perspective of that aid, as well as innovation, investment and experience domestically," Jonathan Glennie, a research fellow at the Overseas Development Institute, writes in the Guardian's "Poverty Matters Blog."

27 Mar 2012

1 in 5 Australians have taken an expired medicine

NPS is urging all Australians to clean out their medicine cabinets today as part of national Be Medicinewise Week 2012. New research from NPS found around 1 in 5 people reported ever having taken an expired medicine.

26 Mar 2012

FDA approves Teva's QNASL nasal aerosol corticosteroid

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has approved QNASL Nasal Aerosol, a new, "dry" nasal aerosol corticosteroid that treats seasonal nasal and year-round nasal allergy symptoms in adults and adolescents 12 years of age and older.

26 Mar 2012

IGI fourth quarter total revenues increase 21% to $2.1M

IGI Laboratories, Inc., a New Jersey based topical generic drug development and manufacturing company, provided its financial results for the fourth quarter and year ended December 31, 2011.

21 Mar 2012

Generic Drug News and Research

Further Reading

HCCI's report shows facility prices outpaced general inflation for the privately insured under 65

Teva first quarter net revenues increase 25% to $5.1 billion

PharMerica first quarter net income increases to $5.6 million

Teva, Mylan settle patent infringement litigation for Nuvigil

Leahy introduces generic drug label legislation

First Edition: April 18, 2012

Supreme Court rules generic drug makers can challenge branded drug companies' wording in patent applications

First Edition: April 18, 2012

Synthon receives tentative approval for tadalafil tablets

Teva's ANDA for Provigil entitled to 180-day exclusivity

Teva reports successful outcome of three debut financings

Teva launches generic Avalide and Avapro Tablets

Teva introduces generic Provigil

Consumer should be centre of care when offering alternative medicine brands

Morning after pills difficult for teenagers to procure

Teva, IVAX receive FDA approval for generic Lexapro to treat depression and GAD

Health solutions developed in lower-income countries will help bring end to aid

1 in 5 Australians have taken an expired medicine

FDA approves Teva's QNASL nasal aerosol corticosteroid

IGI fourth quarter total revenues increase 21% to $2.1M

One Health, One Mission: The World Organisation for Animal Health on the AMR Frontline

Uniting Against Resistance: The World Health Organization for World Antimicrobial Awareness Week 2023

Tackling Antimicrobial Resistance: A Conversation with Dr. Beverley Isherwood

Latest News